Matrix metalloproteinases in peripheral vascular disease

Journal of Vascular Surgery

Volumn 45, Issue 4, 2007, Pages 849-857

  Hobeika, Mark J ^a   Thompson, Robert W ^b   Muhs, Bart E ^a   Brooks, Peter C ^a   Gagne, Paul J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMISTAT; COLLAGENASE 3; DOXYCYCLINE; FLUINDOSTATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMISTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PLACEBO; RO 113 2908; SIMVASTATIN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; HISTOLOGY; HUMAN; LIMB ISCHEMIA; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; ULCER; VARICOSIS;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CONSTRICTION, PATHOLOGIC; ENZYME INHIBITORS; EXTREMITIES; HUMANS; ISCHEMIA; MATRIX METALLOPROTEINASES, SECRETED; PERIPHERAL VASCULAR DISEASES; RECURRENCE; TISSUE INHIBITOR OF METALLOPROTEINASES; VARICOSE ULCER; VARICOSE VEINS; VASCULAR SURGICAL PROCEDURES; VENOUS THROMBOSIS;

EID: 33947608239     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.09.066     Document Type: Review

References (99)

1. Kelleher C.M., McLean S.E., and Mecham R.P. Vascular extracellular matrix and aortic development. Curr Top Dev Biol 62 (2004) 153-188
2. Woessner Jr. J.F. Introduction to serial reviews: the extracellular matrix. Faseb J 7 (1993) 735-736
3. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
4. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
5. Wang Z., Juttermann R., and Soloway P.D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 275 (2000) 26411-26415
6. von Offenberg Sweeney N., Cummins P.M., Birney Y.A., Cullen J.P., Redmond E.M., and Cahill P.A. Cyclic strain-mediated regulation of endothelial matrix metalloproteinase-2 expression and activity. Cardiovasc Res 63 (2004) 625-634
7. Wang B.W., Chang H., Lin S., Kuan P., and Shyu K.G. Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc Res 59 (2003) 460-469
8. Milkiewicz M., Kelland C., Colgan S., and Haas T.L. Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells. J Cell Physiol 208 (2006) 229-237
9. Sinha I., Hannawa K.K., Ailawadi G., Woodrum D.T., Ford J.W., Henke P.K., et al. The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 20 (2006) 92-98
10. Mandal M., Mandal A., Das S., Chakraborti T., and Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 252 (2003) 305-329
11. Soo C., Shaw W.W., Zhang X., Longaker M.T., Howard E.W., and Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 105 (2000) 638-647
12. Krampert M., Bloch W., Sasaki T., Bugnon P., Rulicke T., Wolf E., et al. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell 15 (2004) 5242-5254
13. Zhang J., and Salamonsen L.A. In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87 (2002) 2346-2351
14. Jemal A., Ward E., Hao Y., and Thun M. Trends in the leading causes of death in the United States, 1970-2002. Jama 294 (2005) 1255-1259
15. Plutzky J. The vascular biology of atherosclerosis. Am J Med 115 suppl 8A (2003) 55S-61S
16. Lijnen H.R. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 33 (2003) 275-281
17. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
18. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
19. Jiang X., Zeng H.S., Guo Y., Zhou Z.B., Tang B.S., and Li F.K. The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl) 117 (2004) 1825-1829
20. Brown D.L., Hibbs M.S., Kearney M., Loushin C., and Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 91 (1995) 2125-2131
21. Alvarez B., Ruiz C., Chacon P., Alvarez-Sabin J., and Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 40 (2004) 469-475
22. Apple F.S., Wu A.H., Mair J., Ravkilde J., Panteghini M., Tate J., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51 (2005) 810-824
23. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
24. Halpert I., Sires U.I., Roby J.D., Potter-Perigo S., Wight T.N., Shapiro S.D., et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 93 (1996) 9748-9753
25. Furman C., Copin C., Kandoussi M., Davidson R., Moreau M., McTaggiart F., et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 174 (2004) 93-98
26. Kadoglou N.P., and Liapis C.D. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin 20 (2004) 419-432
27. Ocana E., Bohorquez J.C., Perez-Requena J., Brieva J.A., and Rodriguez C. Characterisation of T and B lymphocytes infiltrating abdominal aortic aneurysms. Atherosclerosis 170 (2003) 39-48
28. Rowe V.L., Stevens S.L., Reddick T.T., Freeman M.B., Donnell R., Carroll R.C., et al. Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas. J Vasc Surg 31 (2000) 567-576
29. Carmo M., Colombo L., Bruno A., Corsi F.R., Roncoroni L., Cuttin M.S., et al. Alteration of elastin, collagen and their cross-links in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 23 (2002) 543-549
30. Duca L., Floquet N., Alix A.J., Haye B., and Debelle L. Elastin as a matrikine. Crit Rev Oncol Hematol 49 (2004) 235-244
31. Nackman G.B., Karkowski F.J., Halpern V.J., Gaetz H.P., and Tilson M.D. Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Surgery 122 (1997) 39-44
32. Senior R.M., Griffin G.L., Fliszar C.J., Shapiro S.D., Goldberg G.I., and Welgus H.G. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 266 (1991) 7870-7875
33. Davis V., Persidskaia R., Baca-Regen L., Itoh Y., Nagase H., Persidsky Y., et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 18 (1998) 1625-1633
34. Crowther M., Goodall S., Jones J.L., Bell P.R., and Thompson M.M. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg 32 (2000) 575-583
35. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110 (2002) 625-632
36. Thompson R.W., Holmes D.R., Mertens R.A., Liao S., Botney M.D., Mecham R.P., et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96 (1995) 318-326
37. Yamashita A., Noma T., Nakazawa A., Saito S., Fujioka K., Zempo N., et al. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. World J Surg 25 (2001) 259-265
38. Hovsepian D.M., Ziporin S.J., Sakurai M.K., Lee J.K., Curci J.A., and Thompson R.W. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 11 (2000) 1345-1352
39. Pyo R., Lee J.K., Shipley J.M., Curci J.A., Mao D., Ziporin S.J., et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105 (2000) 1641-1649
40. Petersen E., Gineitis A., Wagberg F., and Angquist K.A. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 20 (2000) 457-461
41. Eskandari M.K., Vijungco J.D., Flores A., Borensztajn J., Shively V., and Pearce W.H. Enhanced abdominal aortic aneurysm in TIMP-1-deficient mice. J Surg Res 123 (2005) 289-293
42. Allaire E., Forough R., Clowes M., Starcher B., and Clowes A.W. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 102 (1998) 1413-1420
43. Lorelli D.R., Jean-Claude J.M., Fox C.J., Clyne J., Cambria R.A., Seabrook G.R., et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J Vasc Surg 35 (2002) 916-922
44. Sangiorgi G., D'Averio R., Mauriello A., Bondio M., Pontillo M., Castelvecchio S., et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 104 12 suppl 1 (2001) I288-I295
45. Baxter B.T. Could medical intervention work for aortic aneurysms?. Am J Surg 188 (2004) 628-632
46. Steinmetz E.F., Buckley C., and Thompson R.W. Prospects for the medical management of abdominal aortic aneurysms. Vasc Endovascular Surg 37 (2003) 151-163
47. Thompson R.W., and Baxter B.T. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 878 (1999) 159-178
48. Baxter B.T., Pearce W.H., Waltke E.A., Littooy F.N., Hallett Jr. J.W., Kent K.C., et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 36 (2002) 1-12
49. Petrinec D., Liao S., Holmes D.R., Reilly J.M., Parks W.C., and Thompson R.W. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23 (1996) 336-346
50. Mosorin M., Juvonen J., Biancari F., Satta J., Surcel H.M., Leinonen M., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 34 (2001) 606-610
51. Bartoli M.A., Parodi F.E., Chu J., Pagano M.B., Mao D., Baxter B.T., et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 20 (2006) 228-236
52. Steinmetz E.F., Buckley C., Shames M.L., Ennis T.L., Vanvickle-Chavez S.J., Mao D., et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 241 (2005) 92-101
53. Sukhija R., Aronow W.S., Sandhu R., Kakar P., and Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97 (2006) 279-280
54. Schouten O., van Laanen J.H., Boersma E., Vidakovic R., Feringa H.H., Dunkelgrun M., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32 (2006) 21-26
55. Lawrence D.M., Singh R.S., Franklin D.P., Carey D.J., and Elmore J.R. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 40 (2004) 334-338
56. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11 (2005) 1330-1338
57. Scholz D., Ziegelhoeffer T., Helisch A., Wagner S., Friedrich C., Podzuweit T., et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 34 (2002) 775-787
58. Pipp F., Boehm S., Cai W.J., Adili F., Ziegler B., Karanovic G., et al. Elevated fluid shear stress enhances postocclusive collateral artery growth and gene expression in the pig hind limb. Arterioscler Thromb Vasc Biol 24 (2004) 1664-1668
59. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 38 (2003) 198-203
60. Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., and Isner J.M. Mouse model of angiogenesis. Am J Pathol 152 (1998) 1667-1679
61. Muhs B.E., Plitas G., Delgado Y., Ianus I., Shaw J.P., Adelman M.A., et al. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. J Surg Res 111 (2003) 8-15
62. Gagne P.J., Tihonov N., Li X., Glaser J., Qiao J., Silberstein M., et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Am J Pathol 167 (2005) 1349-1359
63. Tayebjee M.H., Tan K.T., MacFadyen R.J., and Lip G.Y. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med 257 (2005) 110-116
64. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169 (2005) 681-691
65. Xu J., Rodriguez D., Kim J.J., and Brooks P.C. Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 19 (2000) 375-385
66. Hangai M., Kitaya N., Xu J., Chan C.K., Kim J.J., Werb Z., et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 161 (2002) 1429-1437
67. Xu J., Rodriguez D., Petitclerc E., Kim J.J., Hangai M., Moon Y.S., et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154 (2001) 1069-1079
68. Jude E.B., Oyibo S.O., Chalmers N., and Boulton A.J. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 24 (2001) 1433-1437
69. Death A.K., Fisher E.J., McGrath K.C., and Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168 (2003) 263-269
70. Schiekofer S., Galasso G., Sato K., Kraus B.J., and Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 25 (2005) 1603-1609
71. Kuzuya M., and Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 10 (2003) 275-282
72. Newby A.C., and Zaltsman A.B. Molecular mechanisms in intimal hyperplasia. J Pathol 190 (2000) 300-309
73. Southgate K.M., Mehta D., Izzat M.B., Newby A.C., and Angelini G.D. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 19 (1999) 1640-1649
74. Margolin L., Fishbein I., Banai S., Golomb G., Reich R., Perez L.S., et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta receptor blockade. Atherosclerosis 163 (2002) 269-277
75. Bendeck M.P., Conte M., Zhang M., Nili N., Strauss B.H., and Farwell S.M. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 160 (2002) 1089-1095
76. Lijnen H.R., Soloway P., and Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ Res 85 (1999) 1186-1191
77. Galis Z.S., Johnson C., Godin D., Magid R., Shipley J.M., Senior R.M., et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91 (2002) 852-859
78. Cho A., and Reidy M.A. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91 (2002) 845-851
79. Kuzuya M., Kanda S., Sasaki T., Tamaya-Mori N., Cheng X.W., Itoh T., et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 108 (2003) 1375-1381
80. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., and Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987) 1371-1375
81. Post M.J., Borst C., Pasterkamp G., and Haudenschild C.C. Arterial remodeling in atherosclerosis and restenosis: a vague concept of a distinct phenomenon. Atherosclerosis 118 suppl (1995) S115-S123
82. de Smet B.J., de Kleijn D., Hanemaaijer R., Verheijen J.H., Robertus L., van Der Helm Y.J., et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 101 (2000) 2962-2967
83. Sierevogel M.J., Pasterkamp G., Velema E., de Jaegere P.P., de Smet B.J., Verheijen J.H., et al. Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation: an intravascular ultrasound study in the pig. Circulation 103 (2001) 302-307
84. Cherr G.S., Motew S.J., Travis J.A., Fingerle J., Fisher L., Brandl M., et al. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler Thromb Vasc Biol 22 (2002) 161-166
85. Araujo C.M., Rando G.A., Mauro M.F., Cristovao S.A., Sanchez I.S., Salman A.A., et al. [Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study]. Arq Bras Cardiol 84 (2005) 256-260
86. Muni N.I., Califf R.M., Foy J.R., Boam A.B., Zuckerman B.D., and Kuntz R.E. Coronary drug-eluting stent development: issues in trial design. Am Heart J 149 (2005) 415-433
87. Lane R.J., and Cuzzilla M.L. Aetiology of varicose veins: haemodynamics. ANZ J Surg 73 (2003) 874-876
88. Kowalewski R., Sobolewski K., Wolanska M., and Gacko M. Matrix metalloproteinases in the vein wall. Int Angiol 23 (2004) 164-169
89. Sansilvestri-Morel P., Rupin A., Jullien N.D., Lembrez N., Mestries-Dubois P., Fabiani J.N., et al. Decreased production of collagen type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3. J Vasc Res 42 (2005) 388-398
90. Prandoni P., Lensing A.W., Cogo A., Cuppini S., Villalta S., Carta M., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
91. Deatrick K.B., Eliason J.L., Lynch E.M., Moore A.J., Dewyer N.A., Varma M.R., et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 42 (2005) 140-148
92. Henke P.K., Varma M.R., Deatrick K.B., Dewyer N.A., Lynch E.M., Moore A.J., et al. Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization. Thromb Haemost 95 (2006) 272-281
93. Dahi S., Lee J.G., Lovett D.H., and Sarkar R. Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. J Vasc Surg 42 (2005) 539-545
94. Trengove N.J., Stacey M.C., MacAuley S., Bennett N., Gibson J., Burslem F., et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 7 (1999) 442-452
95. Saito S., Trovato M.J., You R., Lal B.K., Fasehun F., Padberg Jr. F.T., et al. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34 (2001) 930-938
96. Mwaura B., Mahendran B., Hynes N., Defreitas D., Avalos G., Adegbola T., et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 31 (2006) 306-310
97. Norgauer J., Hildenbrand T., Idzko M., Panther E., Bandemir E., Hartmann M., et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 147 (2002) 1180-1186
98. Ulrich D., Lichtenegger F., Unglaub F., Smeets R., and Pallua N. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg 116 (2005) 539-545
99. Lobmann R., Zemlin C., Motzkau M., Reschke K., and Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications 20 (2006) 329-335